Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (91-100 of 361) with videos related to

Pageof 37
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|May 16, 2019
Germline and Somatic Mutations in Prostate Cancer for the ClinicianHeather H Cheng, Alexandra O Sokolova, Edward M Schaeffer, et al.
Cancer Reports (Hoboken, N.J.)|February 23, 2021
Examining reporting and representation of patients with cancer in COVID-19 clinical trialsMaya Rabow, Christine Wang, Sylvia Zhang, et al.
Cancer|June 1, 2006
Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapyBrian I Rini, Vivian Weinberg, Lawrence Fong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancerSusan Halabi, Nicholas J Vogelzang, San-San Ou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancerCelestia S Higano, Nicholas J Vogelzang, Jeffrey A Sosman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancerEric J Small, N Simon Tchekmedyian, Brian I Rini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B studyCharles J Ryan, Susan Halabi, San-San Ou, et al.
The Journal of Urology|October 16, 2007
Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcomeCharles J Ryan, Vivian Weinberg, Jonathan Rosenberg, et al.
JAMA Oncology|October 27, 2022
Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 PandemicMeera V Ragavan, Nichole Legaspi, Alyssa LaLanne, et al.
Urology|August 11, 2004
Impact of race on survival in men with metastatic hormone-refractory prostate cancerSusan Halabi, Eric J Small, Nicholas J Vogelzang, et al.
Pageof 37

Showing results (91-100 of 361) with videos related to

Sort By:
Pageof 37
Journal of the National Comprehensive Cancer Network : JNCCN|May 16, 2019
Germline and Somatic Mutations in Prostate Cancer for the ClinicianHeather H Cheng, Alexandra O Sokolova, Edward M Schaeffer, et al.
Cancer Reports (Hoboken, N.J.)|February 23, 2021
Examining reporting and representation of patients with cancer in COVID-19 clinical trialsMaya Rabow, Christine Wang, Sylvia Zhang, et al.
Cancer|June 1, 2006
Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapyBrian I Rini, Vivian Weinberg, Lawrence Fong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2009
Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancerSusan Halabi, Nicholas J Vogelzang, San-San Ou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancerCelestia S Higano, Nicholas J Vogelzang, Jeffrey A Sosman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancerEric J Small, N Simon Tchekmedyian, Brian I Rini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B studyCharles J Ryan, Susan Halabi, San-San Ou, et al.
The Journal of Urology|October 16, 2007
Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcomeCharles J Ryan, Vivian Weinberg, Jonathan Rosenberg, et al.
JAMA Oncology|October 27, 2022
Analysis of Serious Adverse Event Reporting for Patients Enrolled in Cancer Clinical Trials During the COVID-19 PandemicMeera V Ragavan, Nichole Legaspi, Alyssa LaLanne, et al.
Urology|August 11, 2004
Impact of race on survival in men with metastatic hormone-refractory prostate cancerSusan Halabi, Eric J Small, Nicholas J Vogelzang, et al.
Pageof 37